First Author
|
Jadad score
|
Inclusion/exclusion criteria specified
|
Randomization process described
|
Use of any blinding
|
Placebo-controlled
|
Reported loss to follow-up
|
Intention-to treat analysis
|
Potential important baseline differences
|
Power calculation
|
---|
Allaqaband
25
|
3
|
yes/no
|
yes
|
yes
|
yes
|
no
|
no
|
no
|
yes
|
Baker
26
|
2
|
yes/yes
|
yes
|
no
|
yes
|
no
|
yes
|
no
|
yes
|
Briguori
27
|
1
|
yes/no
|
yes
|
no
|
no
|
no
|
unclear
|
yes
|
no
|
Diaz-Sandoval
28
|
4
|
yes/yes
|
yes
|
yes
|
no
|
yes
|
unclear
|
yes
|
no
|
Durham
29
|
5
|
yes/yes
|
yes
|
yes
|
yes
|
yes
|
unclear
|
no
|
yes
|
Efrati
30
|
4
|
yes/yes
|
no
|
yes
|
yes
|
yes
|
unclear
|
no
|
no
|
Fung
31
|
4
|
yes/yes
|
yes
|
no
|
no
|
no
|
yes
|
no
|
yes
|
Goldenberg
32
|
5
|
yes/yes
|
yes
|
yes
|
yes
|
no
|
unclear
|
no
|
yes
|
Kay
33
|
5
|
yes/yes
|
yes
|
yes
|
yes
|
yes
|
yes
|
no
|
yes
|
Kefer
34
|
4
|
yes/yes
|
yes
|
yes
|
yes
|
yes
|
unclear
|
yes
|
no
|
MacNeill
35
|
4
|
yes/yes
|
yes
|
no
|
yes
|
no
|
unclear
|
no
|
yes
|
Oldemeyer
36
|
4
|
yes/yes
|
yes
|
yes
|
no
|
yes
|
unclear
|
no
|
no
|
Shyu
37
|
3
|
yes/yes
|
yes
|
yes
|
no
|
yes
|
unclear
|
no
|
no
|
Vallero
38
|
2
|
yes/yes
|
yes
|
no
|
no
|
no
|
unclear
|
yes
|
no
|
- Legend: NR = not recorded or available; Jadad score range 0–5.